MEDSIR, a leading company dedicated to the strategic design of independent clinical research, participated in the Annual Meeting of the American Association for Cancer Research, a premier event that brings together scientists, clinicians, industry professionals, advocates, and other stakeholders in the field of cancer research, presenting the results of two sub-studies focused on biomarkers: transFal, focused on patients with HR+/HER2- advanced breast cancer and METSGain, centered on patients with early breast cancer.
Both studies underscore the importance of utilizing biomarkers. Their early detection has been shown to increase patient survival rates by aiding in selecting the most appropriate treatment for patients.
In the context of personalized medicine, biomarkers are also important for tailoring treatments for individual patients based on their unique biological characteristics, allowing for more precise and effective medical interventions.
These findings represent significant strides in understanding and leveraging biomarkers for personalized cancer care, offering new hope to patients and paving the way for more effective treatment strategies tailored to individual patients‘ biological profiles.
transFAL: Unlocking Biomarkers for HR+/HER2- Advanced Breast Cancer
MEDSIR introduced the results of the transFAL study, aimed at uncovering biomarkers of response or resistance to palbociclib in combination with endocrine therapy-based regimens for patients with HR+/HER2- advanced breast cancer. The study, analyzing samples from the PARSIFAL trial, revealed significant insights into biomarker associations with treatment response. Notably, high expression of Ki67 and CDK6, along with elevated ctDNA density at baseline, were correlated with shorter progression-free survival and overall survival. These findings illuminate potential avenues for understanding and overcoming resistance to CDK4/6 inhibitors, marking a significant step forward in personalized cancer treatment.
METSGain: Predictive Potential in Early Breast Cancer
Additionally, MEDSIR presented findings from the METSGain study, which focused on predicting the risk of distant recurrences and understanding metastatic processes in early breast cancer, analyzing data from the PHERGain trial. The study demonstrated that HER2DX® risk-score measurement after treatment and tumor surgery can provide valuable insights into future distant metastases. Notably, patients with high-risk scores at surgery and less molecular changes after anti-HER2 therapy were more likely to develop metastasis, further highlighting the potential of HER2DX® tool developed by REVEAL GENOMICS S.L. ® in guiding treatment decisions for HER2+ early breast cancer patients.